Stay updated on Pembrolizumab in 1st Line NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in 1st Line NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in 1st Line NSCLC Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The NIH announcement banner about the transition from “Artificial Intelligence” to “Super Intelligence” terminology is no longer displayed. The clinical study record itself remains an error page.
    Difference
    1%
    Check dated 2026-11-08T09:55:14.000Z thumbnail image
  2. Check
    7 days ago
    Change Detected
    Summary
    The footer revision changed from v3.7.2 to v3.8.0. The study record page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T11:25:02.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    A sitewide banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology.
    Difference
    1%
    Check dated 2026-10-25T11:24:47.000Z thumbnail image
  4. Check
    21 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer now identifies the site revision as v3.7.2 instead of v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-18T12:23:04.000Z thumbnail image
  5. Check
    28 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-11T13:33:59.000Z thumbnail image
  6. Check
    50 days ago
    Change Detected
    Summary
    Access to the ClinicalTrials.gov study record for NCT03950674 now returns a 403 Forbidden page instead of the study details. The screen shows a 403 message and a Home button, signaling the record is temporarily inaccessible due to permissions.
    Difference
    22%
    Check dated 2026-09-20T04:32:31.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in 1st Line NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in 1st Line NSCLC Clinical Trial page.